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Abstract
Characteristically, most solid tumors exhibit an increased tumor interstitial fluid pressure (TIFP) that directly con-
tributes to the lowered uptake of macromolecular therapeutics into the tumor interstitium. Abnormalities in the
tumor-associated lymph vessels are a central brick in the development and prolonged sustaining of an increased
TIFP. In the current study, vascular endothelial growth factor C (VEGF-C) was used to enhance tumor-associated
lymphangiogenesis as a new mechanism to actively reduce the TIFP by increased lymphatic drainage of the tumor
tissue. Human A431 epidermoid vulva carcinoma cells were inoculated in NMRI nu/nu mice to generate a xenograft
mousemodel. Seven days after tumor cell injection, VEGF-Cwas peritumorally injected to induce lymphangiogenesis.
Tumor growth and TIFP was lowered significantly over time in VEGF-C–treated tumors in comparison to control
or VEGF-A–treated animals. These data demonstrate for the first time that actively induced lymphangiogenesis can
lower the TIFP in a xenograft tumor model and apparently reduce tumor growth. This model represents a novel
approach to modulate biomechanical properties of the tumor interstitium enabling a lowering of TIFP in vivo.
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Introduction
Elevated tumor interstitial fluid pressure (TIFP) is a common obser-
vation in cancer patients and in experimental tumor models [1–4].
The increased pressure is driven by the abnormal blood and lym-
phatic vasculature in the tumor tissue that is hallmarked by the
highly permeable and chaotic blood vessel network and non-functional
lymphatic drainage [5–7]. The enhanced TIFP is the central bio-
physical protagonist that hampers the enrichment of macromolecular
therapeutics within the tumor [8,9].
It has been shown that tumors seem to lack a functional lymphatic
vascularization and establish high interstitial fluid pressure values,
while in normal tissues excessive fluid is permanently drained by
lymphatic vessels [10]. Respectively, it has been reported that in
tumors that exhibit signs of lymphatic vessel architecture those were
not able to drain tissue fluid. One reason for this phenomenon is
the compression of the lymphatic vascular system in tumor tissue
by proliferating cancer cells [11]. Furthermore, impairment in the
function of the lymphatic valves is under consideration to be another
reason why intratumoral lymphatic vessels feature a non-functional
state [12]. However, immunohistochemical staining against lymphatic
markers often revealed a complete absence of lymph vessels in tumor
tissue [7,13]. Nevertheless, no investigations were undertaken so far to
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investigate how the presence of functional lymphatic vessels in the
tumor tissue influences the TIFP in vivo.
We have previously shown that TIFP induces mechanical stretch
to tumor cells and contributes as a trigger factor to enhanced tumor
cell proliferation [14,15]. Furthermore, we systemically lowered the
TIFP and enabled an increased uptake of pharmaceutical active drugs
into the tumor tissue [16]. In the latter experimental setup, we
applied concentrated human serum albumin as an agent to decrease
the TIFP through an enhanced colloid osmotic pressure [16].
In the current work, we are going to address the hypothesis that
an increase in functional lymphatics can lower the TIFP through an
increased draining of excessive tissue fluid. Subcutaneously, A431
vulva carcinoma–bearing NMRI nude mice were peritumorally
treated with vascular endothelial growth factor C (VEGF-C) to
enhance lymphangiogenesis in the tumor tissue. VEGF-C is a mem-
ber of the VEGF family of vascular growth factors, which comprises
VEGF-A, -B, -C, and -D and Orf virus VEGFs (or VEGF-E)
[17,18]. VEGF-C has been identified to play a crucial role in the
development of the lymphatic system [19,20]. In addition, the trans-
genic overexpression of VEGF-C induced lymphatic vessel enlarge-
ment in the skin, and a recombinant VEGF-C approach induced
lymphangiogenesis in the chick chorioallantoic membrane [21,22].
In the experimental setup, TIFP and tumor growth were measured
and compared with physiologic sodium chloride or VEGF-A–treated
xenograft animals. Our findings indicate that the peritumorally applied
VEGF-C is able to lower the TIFP and, in addition, delays tumor
growth. Immunohistochemical staining of tumor tissue confirmed an
increased lymphatic network after peritumoral VEGF-C application.
This work identifies the importance of a functional lymphatic
system with regard to increased TIFP featured regularly in solid
tumors. It can offer new perspectives for an approach to lower the
TIFP through enhanced lymphangiogenesis and simultaneous
targeting of tumor tissue with macromolecular therapeutics.
Materials and Methods
Drugs and Cells
The A431 epidermoid vulva carcinoma cell line was purchased
from the American Type Culture Collection (ATCC, Manassas, VA)
and was cultured in Dulbecco’s modified Eagle’s medium (Invitrogen,
Karlsruhe, Germany) containing 10% fetal calf serum.
VEGF-A (mBA-165, #sc-4571; Santa Cruz Biotechnology, La Jolla,
CA) and VEGF-C (#DA3519X; Acris Antibodies, Herford, Germany)
were injected peritumorally. Anti–LYVE-1 antibody was obtained
from Abcam (Cambridge, United Kingdom; #ab14917) to identify
lymphatic endothelial cells. Immunofluorescence visualization was
performed using anti-rabbit IgG–fluorescein isothiocyanate secondary
antibody (#F0382; Sigma, Steinheim, Germany).
Tumor Models
Female NMRI nu/nu mice (5-6 weeks; 18-22 g; Janvier Elevage,
Le Genest-Saint-Isle, France) were subcutaneously injected on both
flanks with 5 × 106 A431 cells. All animal experiments were ap-
proved in accordance with the German animal welfare regulations
(Regierungspräsidium Darmstadt, F79/47). The animals were kept
under specific pathogen-free conditions. Sterilized food and tap water
were given ad libitum. Mice were anesthetized using isoflurane gas
anesthesia (Abbott, Wiesbaden, Germany) for TIFP and tumor growth
measurements. For tumor excision, animals were anaesthetized using
ketamine/xylazine (100/10 mg/kg, intraperitoneally; Pharmacia,
Erlangen, Germany and BayerVital, Leverkusen, Germany). All ani-
mals were placed on regulated heating pads to keep the body tem-
perature at 37 to 37.5°C during the experiments. After tumor excision,
anesthetized animals were sacrificed.
Tumor size was measured with calipers every 4 days, starting 7 days
after subcutaneous tumor inoculation, and tumor volume was calcu-
lated as described previously [23,24]. Furthermore, peritumoral in-
jection of VEGF-C (0.5 or 1.0 or 2.0 μg), VEGF-A (1.0 or 2.0 μg),
or physiologic sodium chloride (0.9%) was performed 7 days after
tumor cell injection.
TIFP Measurements
TIFP was evaluated as reported previously using the “wick-in-
needle” technique [14,25,26]. TIFP measurements were done every
4 days using a 27-gauge–sized hollow needle inserted in the outermost
tumor tissue layers. The needle was connected to a clinical pressure
transducer APT 300 (HSE Harvard Apparatus, March-Hugstetten,
Germany). The needle and the adjacent connecting tube were filled
with a physiologic sodium chloride solution. Recording of TIFP started
when tumors reached a volume of ≥500 mm3. Fluid communication
between the needle and the tumor tissue was tested by compressing
and decompressing the tubing, and data were accepted only if the re-
corded pressure returned rapidly to the value before tube compression.
Immunohistochemical Staining
Ki-67 immunohistochemical staining was performed using tumors
fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin.
Sectioning was performed using a Leica RM2125 rotary microtome
(Leica Microsystems, Wetzlar, Germany). Subsequently, tumor sec-
tions were dried for 15 minutes at 65°C, deparaffinized in xylene, re-
hydrated in series of graded alcohols, rinsed in distilled water followed
by heat-induced epitope retrieval in 10 mM citrate buffer (pH 6.0;
DakoCytomation, Hamburg, Germany). Then, tissue sections were
cooled for 20 minutes, washed [3% H2O2, 0.1% Triton–phosphate-
buffered saline (PBS), 2% glycine-PBS], and incubated for 10 minutes
with protein blocking agent (Immunotech, Marseille, France). Con-
secutively, sections were incubated with anti-human Ki-67 (clone
MIB-1, 1:50 in PBS; DakoCytomation) for 1 hour at room tempera-
ture. After three washes in PBS, sections were incubated with a bio-
tinylated secondary antibody and streptavidin peroxidase reagent
(Immunotech) for 45 minutes. Staining was performed using the
AEC peroxidase substrate kit (Vector Laboratories, Burlingame, CA).
Finally, sections were counterstained using Mayer’s hematoxylin
(AppliChem, Darmstadt, Germany).
Immunofluorescence
For immunofluorescence studies of lymphangiogenesis, tumors
were embedded in TissueTek-Medium (Jung, Heidelberg, Germany)
and immediately frozen. Frozen samples were cut in thin slices of 8 to
12 μm using a Leica Kryostat (Leica Microsystems) and placed on ob-
ject slides. Slides were fixed using cold acetone (−20°C), incubated
with anti–LYVE-1 antibody (1:200) for 2 hours at room temperature,
and subsequently incubated with fluorescein isothiocyanate–coupled
anti-rabbit antibody (1:100, 1 hour at room temperature). Afterward,
slides were washed, mounted, and stored at 4°C in nontransparent
boxes to protect fluorescent dyes from bleaching. Sections were
examined using a BZ8000 fluorescence microscope (Keyence, Neu-
Isenburg, Germany).
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Quantification of Apoptotic Tumor Cells
The ApopTag Red In Situ Apoptosis Detection Kit (S7165;
Chemicon, Temecula, CA) was used to assess cellular apoptosis in
frozen sections of tumor tissue that employs terminal deoxynucleo-
tidyl transferase–mediated deoxyuridine triphosphate (dUTP) nick
end labeling (TUNEL) methodology. Frozen slides were fixed for
10 minutes in 1% paraformaldehyde in PBS, washed with PBS, in-
cubated for 5 minutes in −20°C cold ethanol–acetic acid, and washed
with PBS. After quenching of endogenous peroxidase activity, sam-
ples were incubated with a terminal deoxynucleotidyl transferase en-
zyme mix (60 minutes at 37°C in a humidified chamber). This step
was followed by the incubation of the slides with anti-digoxigenin
conjugate for 30 minutes in a light-protected humidified environment.
Finally, slides were washed, counterstained, and embedded. We per-
formed nuclear counterstaining using 4′,6-diamidino-2-phenylindole
dihydrochloride (AppliChem).
Results
Lowered Tumor Growth Rate in VEGF-C–Treated
Xenograft Mice
Initially, we recorded the increase of tumor growth in VEGF-C–
treated mice versus sodium chloride–treated control animals employing
the A431 tumor xenograft model (NMRI nu/nu mice). Therefore,
NMRI nude mice were subcutaneously inoculated into the left and
right parts of the back with A431 tumor cells. We found that the
tumor growth was significantly reduced in all animals treated with
VEGF-C that was applied in a peritumoral region 1 week after the
inoculation of the tumor cells. Already at 8 days after the VEGF-C
application in A431 tumor cells, a significant decrease in tumor
growth was visible in the 0.5 (284 ± 26 mm3) and 1.0 μg (258 ±
26 mm3) treated animals in comparison to the control group (707 ±
85 mm3). At 16 days, all three VEGF-C–treated groups (0.5,
1.0, and 2.0 μg) showed a significant reduction in tumor vol-
ume (Figure 1A). While control tumors reached a volume of 2051
(±259) mm3, the VEGF-C–treated tumors exhibit tumor volumes of
836 ± 191 mm3 (0.5 μg), 692 ± 90 mm3 (1.0 μg), and 1097 ±
155 mm3 (2.0 μg), respectively.
In addition, we tested if the measured effect is specific for VEGF-C
or related to the family of VEGFs; we repeated the experiment with
VEGF-A, an angiogenesis-related endothelial growth factor. In the
new investigation, VEGF-A was applied peritumorally according
to the previous VEGF-C experiments. The injections were performed
using 1.0 or 2.0 μg of VEGF-A, respectively. In comparison to the
previous results of VEGF-C–treated animals, the peritumoral applica-
tion of VEGF-A significantly increased the tumor growth of the
A431 tumors compared to control tissue (Figure 1B).
Tumor Growth Is Decreased due to Lowered Tumor
Cell Proliferation
Herein, we investigated if the decelerated tumor growth is due to a
reduced tumor cell proliferation or as a result of an increased tumor
cell apoptosis. Tumors were excised 7 days after the peritumoral
application of VEGF-C to assess cellular apoptosis and cellular
proliferation by TUNEL staining or Ki-67 immunohistochemical
staining, respectively. Figure 2, A to D, visualizes the results of
TUNEL staining for tissue samples of VEGF-C–treated and control
tumors. All slides show a similar pattern and number of apoptotic
tumor cells. No significant changes are visible between the groups.
In contrast, immunohistochemical staining against the cellular pro-
liferation marker Ki-67 revealed a reduced staining in the VEGF-C–
treated tumor tissue (Figure 2, F–H ) compared to untreated control
tumor tissue (Figure 2E ). These findings show that the tumor
growth rate in VEGF-C–treated tumors is lowered as a result of a
decreased tumor cell proliferation, while tumor cell apoptosis is not
affected by the VEGF-C application.
VEGF-C–induced Lymphangiogenesis in A431 Tumors
To clarify if the peritumoral application of VEGF-C enhanced
lymphangiogenesis in tumor tissue, we excised tumors from all treat-
ment groups at a size of approximately 1000 mm3 and performed
immunohistochemical staining with anti–LYVE-1. The antibody
Figure 1.Measurement of tumor growth. (A) Peritumoral application of VEGF-C (0.5, 1.0, and 2.0 μg) at day 0. Tumor growth wasmeasured
every 4 days using a digital caliper. Data are shown as mean (±SEM) increase of TIFP (n = 10). (B) Peritumoral application of VEGF-A
(1.0 and 2.0 μg) at day 0. Tumor growth was measured every 4 days using a digital caliper. Data are shown as mean (±SEM) increase
of TIFP (n = 10). For both graphs, *P = .05, **P = .01, and ***P = .001, treatment versus control.
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binds specific to lymphatic vessel endothelial hyaluronan receptor 1,
which is expressed on lymphatic endothelial cells and the hepatic
sinusoidal endothelium but not on vascular endothelial cells. There-
fore, LYVE-1 staining can be used as a lymphatic endothelial marker
[27]. As shown in Figure 3, all VEGF-C–treated tumors highlighted
a strong LYVE-1 signal. In comparison to the control tissue that pres-
ents only a slight background staining (Figure 3A), tissues of VEGF-
C–treated tumors show distinct lymphangiogenesis and lymphatic
vessels in the tumor tissue (Figure 3, B–D). Our results also indi-
cated an increased level of lymphangiogenesis in tumors treated with
1.0 or 2.0 μg of VEGF-C compared to tumors that received a peritu-
moral application of 0.5 μg of VEGF-C. Tumor tissue sections of
VEGF-A–treated animals featured no LYVE-1–positive staining (data
not shown).
Figure 2. VEGF-C–treated tumors exhibit reduced tumor cell growth but no increase in tumor cell apoptosis. Cellular apoptosis was
identified after TUNEL staining of frozen tumor tissue section of (A) control animals or (B) 0.5-μg VEGF-C–, (C) 1.0-μg VEGF-C–, or
(D) 2.0-μg VEGF-C–treated animals. Apoptotic cells are red labeled. Frozen sections were counterstained using 4′,6-diamidino-2-
phenylindole dihydrochloride. Tumor cell proliferation was assessed by immunohistochemical staining of paraffin-embedded tumor
tissue section of (E) control animals or (F) 0.5-μg VEGF-C–, (G) 1.0-μg VEGF-C–, or (H) 2.0-μg VEGF-C–treated animals against the cellular
proliferation marker Ki-67. Slides were counterstained using Mayer’s hematoxylin.
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Reduced Tumor Interstitial Fluid Pressure in
VEGF-C–Treated Xenograft Mice
To determine if the VEGF-C–induced lymphatic network influ-
ences the TIFP, we used the “wick-in-needle” technique to measure
TIFP intratumorally. We started the measurement at day 8 and with
a minimum tumor volume of approximately 500 mm3. The TIFP
measurement was performed every 4 days. A significant reduction in
TIFP is visible for all VEGF-C–treated animals at day 16 in comparison
to the sodium chloride–treated control mice (Figure 4). Animals that
were previously treated with 1.0 μg of VEGF-C exhibit the highest
reduction in TIFP. At day 16, TIFP values of 5.5 (±0.5) mm Hg for
1.0 μg of VEGF-C versus 11.7 (±0.6) mm Hg for the control animals
were measured. Furthermore, TIFP values were 8.9 (±1.1) mm Hg for
0.5 μg of VEGF-C and 7.5 (±0.5) mm Hg for 2.0 μg of VEGF-C,
respectively. Both values were also significantly lower compared to
the control tumors.
Discussion
Elevated TIFP is known to hamper the uptake of macromolecular
molecules due to a reduced convectionally driven transendothelial
fluid transport [28]. Particularly, the transport and uptake of thera-
peutic drugs, e.g., monoclonal antibodies, is reduced, contributing
to a lowered retention time of chemotherapeutics within tumor tissue
[3,29,30]. The lack of a functional lymphatic drainage has been pro-
posed as a key factor in the development of increased values of TIFP
in human and experimental tumors [10].
Here, we pursued a new approach to lower the TIFP, highlighting
the importance of the lymphatic vasculature in the development and
homeostasis of high TIFP values. Initially, VEGF-C was administered
peritumoral of vulva carcinoma–derived epithelial A431 tumors that
were grown subcutaneously in immunosuppressed NMRI nu/nu
mice. As reported previously, A431 tumors exhibit increased TIFP
values of up to 15 mm Hg and show a strong correlation between
TIFP and tumor volume [14,16]. Respectively, it has been shown
by others that TIFP increases with the tumor volume in a number of
different tumor species [1,31–33]. In our investigations, we examined
Figure 3. VEGF-C induced intratumoral lymphangiogenesis in A431 tumors. Immunohistochemical staining of frozen tissue sections
of (A) control animals or (B) 0.5-μg VEGF-C–, (C) 1.0-μg VEGF-C–, or (D) 2.0-μg VEGF-C–treated animals against the lymph-specific
endothelial marker LYVE-1. Staining was performed on day 12 after the application of VEGF-C.
Figure 4. TIFP decrease in VEGF-C–treated animals. TIFP was
measured for the first time at day 8 starting at a tumor volume of
approximately 500mm3. TIFPmeasurements were performed every
4 days consecutively. Data are shown as mean (±SEM) increase
of TIFP (n = 4 per group). *P = .05, **P = .01, and ***P = .001,
treatment versus control.
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the tumor growth in regard to the treatment with different concentra-
tions of VEGF-C. The tumor growth rate was significantly reduced
in VEGF-C–treated animals compared with sodium chloride– or
VEGF-A–treated mice. Immunohistochemical stainings confirmed
that the reduced growth rate of VEGF-C–treated tumors was due to
a decreased tumor cell proliferation rate and not apoptosis induced.
Hence, we investigated the lymphatic architecture in A431 tumors
and found an enhanced lymphatic vascularization in VEGF-C–treated
tumors. In addition, a lowered TIFP was measured in mice after being
treated peritumorally with VEGF-C. This reduction in TIFP can be
explained by the enhanced lymphatic drainage of the tumor inter-
stitium after the VEGF-C application. Furthermore, the investigation
of reduced tumor growth is in concert with our previous findings that
lowered TIFP reduces tumor growth through mechanical relaxation of
the tumor cortex [14,15]. However, studies performed in osteosarcoma
cells identified increased VEGF-C levels in tumor cells grown under
pressure compared to benign osteoblast values that expressed low
VEGF-C levels under the same high pressure cell culture environment
[34]. These findings indicate that tumor cells are more sensitive to
pressure gradients in interstitial fluid than normal cells. Nevertheless,
those findings are preliminary as they have been performed in cell
culture and not in tumor models. The current in vivo data do not
corroborate an increased lymphatic network in tumors with high TIFP
levels in comparison to tumors with low TIFP.
Previous attempts to increase the functional lymphatic vasculature
in tumor tissue through overexpression of VEGF-C in tumor cells
were capable to induce the formation of functional lymphatics [12].
Nevertheless, those lymphatics were immature and unable to prevent
lateral flow into side lymphatics [12]. In our attempt, we induced
lymphangiogenesis by applying VEGF-C directly by subcutaneous
peritumoral injection. This induced and established intratumoral
lymphatic vascularization of the tumor tissue. The significant reduc-
tion of TIFP after the administration of VEGF-C can be used as a
marker for a functional draining of excessive interstitial fluid. Yet,
we cannot affirm that the functionality of the newly developed intra-
tumoral lymphatics equates the drainage capacity of lymphatics outside
of the tumor tissue.
In addition, peritumoral application of VEGF-A enhanced tumor
growth but did not exhibit a significant effect on the growth of new
intratumoral lymphatics in our experimental setup. On a first glance,
this finding is in contrary to a range of publications showing that
VEGF-A can induce hemangiogenesis and lymphangiogenesis. A closer
look reveals that tissue inflammation might play a crucial role in the
ability of VEGF-A to induce lymphangiogenesis [35,36]. It is supposed
that VEGF-A mediates lymphangiogenesis by binding to the VEGF
receptor 1 and recruiting of macrophages, which, in turn, can release
additional lymphangiogenic markers [35]. Furthermore, VEGF-A was
identified to promote lymphangiogenesis in VEGF-A–overexpressing
transgenic animals [37]. However, VEGF-A–transfected H293 could
not induce lymphangiogenesis due to lower expression levels of
VEGF-A in comparison with transgenic approaches [38]. We assume
that a single peritumoral injection as used in our experiment did not
provide a VEGF-A level for the induction of lymphangiogenesis.
It has been proven that an increased lymphangiogenesis has a
high therapeutic potential in the treatment of lymphedema [39]. Here,
we show that using the TIFP-lowering effect of lymphangiogenesis
can propose a new approach to increase the uptake of macromolecular
therapeutics into tumor tissue. However, it has to be kept in mind that
the hypothesized usage of a pro-lymphangiogenic treatment of tumors
with the aim of reducing the TIFP has a critical bottleneck that needs
to be precluded prior. The active recruitment of functional lymphatic
vessels into the tumor can increase the risk of lymphatic tumor cell
metastasis. It is known that functional lymphatics in the margin of
the tumor surface are sufficient for lymphatic-driven metastasis and
intratumoral lymphatic vessels are not necessary for the tumor cells
to metastasize [13]. Furthermore, enhanced lymphatic metastasis has
been shown previously in VEGF-C–overexpressing tumors indicating
that increased VEGF-C levels potentiate the risk of lymphatic metas-
tases significantly [13,40]. During the time course of our experiments,
we could not identify an increased risk of metastases in the VEGF-C–
treated xenograft animals. Further investigations will have to take
place including sentinel lymph node excisions to investigate the risk
of increased metastasis due to improved lymphatic drainage of the
tumor tissue.
In conclusion, our data show for the first time that the peritumoral
application of VEGF-C induces lymphangiogenesis and lowers TIFP in
the herein used animal model. Moreover, it was shown that besides
lowering of TIFP, VEGF-C–treated tumors also exhibited a delayed
growth rate. Thus, the present work displays new insights into the
importance of the lymphatic vasculature pertaining to the development
and maintenance of high TIFP in solid tumors.
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